Patent / Technology Valuation: Relief-from-Royalty vs Excess Earnings Case Study
₹30.00 cr
Current technology-attributable revenue4.50%
Selected royalty rate6 years
Economic life used in valuation₹5.10 cr
Concluded patent / technology value01. A Patent with Nine Years Left—But Only Six Years of Economic Value
The subject technology was a patented machine-vision and process-optimisation platform embedded in industrial automation systems. The company sold finished solutions using the technology and also licensed selected modules to third-party integrators.
The patent had been filed on 1 April 2015. At the 31 March 2026 valuation date, approximately 9 years of the 20-year statutory patent term remained. However, management expected the current technology architecture to be commercially overtaken by newer AI-enabled platforms before the legal term expired.
Technology-attributable revenue was approximately ₹30.00 crore in the current year. Revenue was expected to increase for several years as adoption expanded, then mature as competing solutions reduced pricing power and licensing demand.
Elite Valuation was engaged to determine an arm’s-length value for the patent/technology using an income approach and to cross-check whether the royalty-savings conclusion was consistent with the incremental earnings attributable to the patented platform.
“Legal protection sets the outer boundary of patent life. Economic life determines how long market participants actually expect the technology to generate incremental cash flow.”
02. Six Judgements Behind the Patent Value
The difficult part was not discounting royalty cash flows—it was identifying the right revenue base, royalty rate, life and contribution of other assets.
| Challenge Area | Description & Valuation Impact |
|---|---|
| Technology Revenue BaseAttribution Risk | Not every rupee of company revenue was generated by the patent. Only revenue from products and licences materially dependent on the protected technology was included in the royalty base. |
| Royalty Rate SelectionMarket Evidence | The selected 4.50% rate had to reflect comparable technology licences, profitability, exclusivity, remaining life, maintenance burden and the relative importance of the patent to the licensed product. |
| Legal vs Economic LifeObsolescence | The patent had nine legal years left, but technology obsolescence was expected to limit meaningful cash flows to six years. Extending value mechanically to legal expiry would overstate the asset. |
| Tax Amortisation / Tax EffectAfter-Tax Cash Flow | Royalty savings were valued after tax. The analysis kept tax effects consistent with the valuation premise rather than mixing pre-tax royalty benchmarks with after-tax discounting. |
| Contributory AssetsDouble-Count Risk | The excess-earnings cross-check deducted charges for working capital, fixed assets, assembled workforce and supporting software so that those complementary assets were not attributed to the patent. |
| Terminal ValueFinite-Life Asset | No perpetual terminal value was used. The asset was valued only through its six-year economic life because the current patented technology was expected to be superseded. |
03. Relief-from-Royalty as Primary Method, Excess Earnings as Cross-Check
The primary method asked what a market participant would pay as a royalty if it did not own the patent. The cross-check asked how much incremental after-tax earnings remained after paying for all other contributory assets.
Phase A: Forecast technology-attributable revenue
Revenue attributable to the patented platform was forecast at ₹30.00, ₹35.00, ₹41.00, ₹47.00, ₹52.00 and ₹55.00 crore over the six-year economic life.
Phase B: Select the 4.50% royalty rate
Comparable technology licences were screened for industry relevance, exclusivity, territory and stage of technology. After profitability and asset-importance adjustments, a 4.50% royalty rate was selected.
Phase C: Calculate after-tax royalty savings
Annual royalty savings equalled revenue × 4.50%, reduced by a 25.00% tax rate. Year-1 after-tax royalty savings were therefore ₹30.00 crore × 4.50% × 75% = ₹1.0125 crore.
Phase D: Discount only through the six-year economic life
The royalty savings were discounted at 17.00%. No terminal value was added after Year 6. The present value of the six-year royalty stream was approximately ₹4.96 crore.
Phase E: Cross-check using Multi-Period Excess Earnings
The MPEEM isolated technology-related earnings and deducted contributory asset charges for working capital, fixed assets, workforce and supporting software. The resulting after-tax technology excess earnings of ₹1.20–₹1.80 crore per year, discounted at 18.00%, produced approximately ₹5.33 crore.
Phase F: Reconcile to the final patent value
Relief-from-Royalty was weighted 70% because observable licensing economics were available, while MPEEM received 30% as a cross-check: ₹4.96 × 70% + ₹5.33 × 30% = approximately ₹5.07 crore. The final conclusion was rounded to ₹5.10 crore.
6 patent / technology valuation components applied:
Technology Revenue Forecast
Only revenue materially dependent on the patented platform entered the valuation base.
Royalty Benchmarking
Comparable licences were adjusted to a selected 4.50% arm’s-length royalty rate.
Finite-Life Discounting
Six years of economic cash flow were discounted at 17.00% with no perpetual terminal value.
MPEEM Cross-Check
Technology excess earnings were isolated after contributory asset charges.
Legal / Economic Life Review
Nine years of legal term remained, but six years of economic benefit were supportable.
Method Reconciliation
70:30 weighting produced approximately ₹5.07 crore, rounded to ₹5.10 crore.
Relief-from-Royalty calculation:
| Year | Technology Revenue | 4.50% Royalty | After Tax @ 25% | PV @ 17% |
|---|---|---|---|---|
| 1 | ₹30.00 cr | ₹1.35 cr | ₹1.01 cr | ₹0.87 cr |
| 2 | ₹35.00 cr | ₹1.58 cr | ₹1.18 cr | ₹0.86 cr |
| 3 | ₹41.00 cr | ₹1.85 cr | ₹1.38 cr | ₹0.86 cr |
| 4 | ₹47.00 cr | ₹2.12 cr | ₹1.59 cr | ₹0.85 cr |
| 5 | ₹52.00 cr | ₹2.34 cr | ₹1.76 cr | ₹0.80 cr |
| 6 | ₹55.00 cr | ₹2.48 cr | ₹1.86 cr | ₹0.72 cr |
| Relief-from-Royalty value | ₹4.96 cr | |||
Economic life vs legal life:
| Factor | Assessment | Valuation Treatment |
|---|---|---|
| Patent filing date | 1 April 2015 | 20-year statutory term measured from filing |
| Legal expiry | 31 March 2035 | Approximately 9 years remaining at valuation date |
| Technology obsolescence | New AI architectures expected within 5–7 years | Shortens commercial benefit period |
| Customer migration cycle | Gradual replacement, not immediate | Supports declining but continuing benefits through Year 6 |
| Selected economic life | 6 years | Shorter than remaining legal term |
Method reconciliation:
| Method | Indicated Value | Weight | Weighted Value |
|---|---|---|---|
| Relief-from-Royalty | ₹4.96 cr | 70% | ₹3.47 cr |
| Multi-Period Excess Earnings | ₹5.33 cr | 30% | ₹1.60 cr |
| Reconciled value | — | 100% | ₹5.07 cr ≈ ₹5.10 cr |
Patent-life and fair-value framework considered
Patents Act, 1970 — Section 53: the statutory term of an Indian patent is generally 20 years from the filing date, subject to the Act and continued effectiveness of the patent.
Economic life can be shorter than legal life: technology valuation considers obsolescence, product life cycle, competition, demand and expected use. A patent should not be valued through its full legal term where market participants expect the technology to become economically obsolete sooner.
Ind AS 38 principle: for financial-reporting purposes, the useful life of an intangible arising from legal rights cannot exceed the legal term and may be shorter. Where economic and legal factors differ, the shorter supportable period drives useful life.
Ind AS 113 fair-value principle: where fair value is required, the measurement reflects a market-participant exit price at the measurement date. Royalty rates, discount rates, economic life and contributory-asset assumptions should therefore reflect market-participant economics rather than entity-specific optimism.
Purpose matters: this case illustrates economic/fair-value methodology. Patent value for litigation, tax, licensing, financial reporting or transfer pricing may require additional purpose-specific assumptions and legal analysis.
04. Result: ₹5.10 Crore Value Despite Nine Years of Patent Term Remaining
The conclusion was driven by the period of economic benefit, not the maximum legal term printed on the patent certificate.
₹30.00 cr
Current technology-attributable revenue4.50%
Selected royalty rate6 years
Economic life used in valuation₹5.10 cr
Concluded patent / technology value- The patent’s nine remaining legal years were not automatically used; expected technological obsolescence shortened the economic cash-flow period to six years.
- A 4.50% royalty rate applied to the technology revenue forecast produced a ₹4.96 crore Relief-from-Royalty value.
- The ₹5.33 crore MPEEM cross-check independently supported the primary result after charging for workforce, working capital, fixed assets and supporting software.
- No terminal value was used after Year 6, avoiding the common error of treating a finite-life patent as a perpetual asset.
- The 70:30 reconciliation concluded approximately ₹5.07 crore, rounded to a final ₹5.10 crore patent/technology value.
05. Five Lessons from Patent / Technology Valuation
Patent value depends on the economics protected by the right—not simply the existence or remaining term of the patent.
Legal life is an outer limit, not automatically the valuation period
The patent could legally remain protected for nine more years, but technological change supported only six years of economic benefit.
Use only revenue that actually depends on the patent
The royalty base excluded unrelated company revenue. Including all company sales would have overstated royalty savings and patent value.
A royalty benchmark needs economic adjustment
Comparable licence rates differ by exclusivity, territory, technology maturity, profitability and rights granted. The 4.50% rate was selected after those differences were considered.
Excess earnings are useful for catching double counting
The MPEEM cross-check forced the valuation to charge for workforce, fixed assets and supporting software instead of attributing every incremental rupee to the patent.
A finite-life patent normally does not justify a perpetual terminal value
Once the current technology was expected to lose economic relevance, no perpetual royalty stream was added merely because the business itself would continue.
Why Choose Elite Valuation for Patent & Technology Valuation Services
Elite Valuation supports technology companies, patent owners, investors and transaction teams with patent, software and broader intangible-asset Valuation.
For technology assignments, the firm combines royalty benchmarking, Relief-from-Royalty, MPEEM, contributory-asset charges, economic-life analysis and market-participant discount rates rather than valuing intellectual property from legal life or historical development cost alone.
Led by Sagar Shah (CA, CS, IBBI Registered Valuer), Elite Valuation can support transaction, financial-reporting, licensing, restructuring and other purpose-specific intangible-asset requirements.
Sagar Shah — CA | CS | IBBI Registered Valuer
Founder, Elite Valuation
Sagar Shah is the founder of Elite Valuation and a qualified Chartered Accountant, Company Secretary, and IBBI Registered Valuer with prior experience at Ernst & Young. He specialises in business Valuation, M&A advisory, ESOP Valuation, FEMA compliance, and regulatory Valuation across the Companies Act, SEBI, and RBI frameworks. Elite Valuation operates pan-India from Ahmedabad, advising companies of all stages and sizes.
